News

GPB Scientific Announces Initial Availability of Advanced Cell Separation Platform; Name Change to Curate Biosciences

CARLSBAD, Calif., /PRNewswire/ — GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company’s advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the system‘s upcoming commercial introduction. Anticipating the commercial launch, the company is changing its name to “Curate Biosciences” to better communicate its benefits to the gene and cell therapy industry

Cell therapies, typically made from a patient’s own cells, are increasingly important in the fight against cancer and other critical diseases. Curate Biosciences provides a superior cell separation, wash, and concentration solution to deliver more biologically potent results for revolutionary cell therapy treatments. 

The company’s Curate® Cell Processing System is a robust, simple, and automated system that has the potential to enable up to a 50% reduction in the total cost of autologous cell therapy production and a like reduction in the days required to produce a CAR-T dose. The Curate System more than doubles the recovery of patient-derived white blood cells and CD3+ T cell subsets, with exceptional purity in a single-step, closed microfluidic system. 

“Users are now testing the Curate System via our Technology Access Program and observing firsthand its innovative and industry leading ability to produce more high-quality white blood cells for CAR-T oncology cures,” said Mike Grisham, Curate Bioscience’s Chief Executive Officer. “GPB in our prior company name stood for getting people better,’ and this remains our core mission, but the new name reflects our unique capacity to provide more high-quality cells to produce cures for once-intractable diseases.

For more information visit https://www.curatebio.com/

Recent News

03/28/2024

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases,  announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure

03/28/2024

AMPEL BioSolutions’ Lupus Test Launches to Predict Flares & Drug Targets

AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus.  Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI. The LuGENE® lab test is now launching at

03/27/2024

Shaping Tomorrow’s Innovators: LifeNet Health’s Educational Partnership Ignites Student Passion in Life Science

LifeNet Health, a global leader in regenerative medicine, recently collaborated with AP biology students at Landstown High School to offer hands‐on learning experiences with human tissue and cellular solutions. This initiative is part of the Life Sciences Virginia pilot program, which aims to foster interest in life science careers among students and cultivate a talent